Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully-qualified, fraud-free GranuFlo and NaturaLyte cases. Here at Leading Justice, we can customize your firm’s GranuFlo and NaturaLyte advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of GranuFlo and NaturaLyte advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, meaning any data we generate that doesn’t qualify for the target campaign is reviewed to determine whether it is eligible for another type of claim. By using advanced approaches to target contacts specifically related to GranuFlo or NaturaLyte use and side effects like heart attack or death, Leading Justice will increase your firm’s GranuFlo and NaturaLyte case load. If you are interested in helping victims of heart attack and other devastating side effects allegedly linked to the dialysis compounds, our vast consumer reach and direct advertising strategies at Leading Justice give you the confidence and competitive edge to allocate your full budget, with the knowledge that your money is being used in the best way possible.
Every law firm we work with at Leading Justice plays an important role in how we classify claims as qualified or not. And while our experience working alongside plaintiff law firms allows us to recognize a great case when we see one, we will customize our GranuFlo and NaturaLyte case intake specifications to the exact criteria you are seeking. So, if your firm has certain GranuFlo or NaturaLyte qualifying case criteria they would like us to use, we will train our intake specialists to add your specific criteria to every phone call and email they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of GranuFlo and NaturaLyte data with no chance of fraud.
Our Take on GranuFlo & NaturaLyte
GranuFlo and NaturaLyte are brand names of acid concentrates commonly used during dialysis treatment in patients with kidney failure, and both products are manufactured by Fresenius Medical Care – the world’s largest provider of dialysis products and services. The dialysis products were being used in thousands of clinics around the world until March 2012, when the FDA issued a Class I recall of both GranuFlo and NaturaLyte. With the recall, the agency warned consumers and medical professionals that use of the products can lead to low blood pressure and cardiac arrhythmia, which “may culminate in cardiopulmonary arrest” or other serious medical conditions, including death.
According to an internal memo dated November 2011, Fresenius Medical Care was aware of the dangers associated with GranuFlo and NaturaLyte, yet failed to share these risks with the public. In the memo, FMC noted that more than 900 patients had suffered heart attacks in Fresenius dialysis clinics in 2010 alone. The company also linked GranuFlo use to elevated bicarbonate levels and determined that patients with excessive levels of bicarbonate in their blood were a shocking six times more likely to experience cardiac arrest than patients with normal levels. Since this information was brought to light, hundreds of product liability lawsuits have been filed against Fresenius, claiming that the company intentionally put patients in harm’s way to protect its bottom line.